Company Shenzhen YHLO Biotech Co., Ltd.
Equities
688575
CNE100005204
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.67 CNY | +0.07% |
|
-5.14% | -3.73% |
Business description: Shenzhen YHLO Biotech Co., Ltd.
Number of employees: 1,678
Sales by Activity: Shenzhen YHLO Biotech Co., Ltd.
| Fiscal Period: December | 2020 (CNY) | 2021 (CNY) | 2022 (CNY) | 2023 (CNY) | 2024 (CNY) |
|---|---|---|---|---|---|
Diagnostic Kits / Equipment | 999M | 1.18B | 3.98B | 2.05B | 2.01B |
Geographical breakdown of sales: Shenzhen YHLO Biotech Co., Ltd.
| Fiscal Period: December | 2020 (CNY) | 2021 (CNY) | 2022 (CNY) | 2023 (CNY) | 2024 (CNY) |
|---|---|---|---|---|---|
China | - | - | 2.2B | 1.85B | 1.72B |
Overseas | 206M | 179M | 1.73B | 164M | 250M |
Northeast Region | 14.42M | 24.78M | - | - | - |
Northwest District | 19.59M | 30.89M | - | - | - |
Southwest Region | 25.2M | 36.04M | - | - | - |
Northern Region | 42.69M | 60.84M | - | - | - |
Central China | 57.91M | 62.89M | - | - | - |
East China | 153M | 226M | - | - | - |
South China | 444M | 513M | - | - | - |
Executive Committee: Shenzhen YHLO Biotech Co., Ltd.
| Manager | Title | Age | Since |
|---|---|---|---|
Yong Bo Song
CEO | Chief Executive Officer | 42 | 30/11/2012 |
Li Sheng Liao
DFI | Director of Finance/CFO | 47 | 21/12/2022 |
Chun Gen Qian
CTO | Chief Tech/Sci/R&D Officer | 44 | 30/09/2015 |
Ya Nan Shao
IRC | Investor Relations Contact | 33 | - |
Ming Yang Wang
SEC | Corporate Secretary | 37 | 25/10/2023 |
Composition of the Board of Directors: Shenzhen YHLO Biotech Co., Ltd.
| Director | Title | Age | Since |
|---|---|---|---|
Chun Mao Shi
BRD | Director/Board Member | 56 | 09/10/2023 |
Kun Hui Hu
CHM | Chairman | 35 | 31/12/2017 |
Yong Bo Song
CHM | Chairman | 42 | 30/11/2012 |
Deng Ming Liu
BRD | Director/Board Member | 51 | 27/06/2019 |
Wen Ya Yang
BRD | Director/Board Member | 47 | 30/06/2015 |
Xiao Hui Ye
CHM | Chairman | 48 | 15/02/2023 |
Chun Gen Qian
BRD | Director/Board Member | 44 | 03/11/2020 |
Xue Jin Li
BRD | Director/Board Member | 59 | 03/11/2021 |
Hui Chong Wang
BRD | Director/Board Member | 44 | 03/11/2021 |
Li Sheng Liao
BRD | Director/Board Member | 47 | 21/12/2022 |
Company details: Shenzhen YHLO Biotech Co., Ltd.
Shenzhen YHLO Biotech Co., Ltd.
Building 1, YHLO Biotech Plant
518116, Shenzhen
+86 755 2660 1910
http://www.szyhlo.com
Medical Equipment
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.07% | -5.14% | -16.03% | -36.42% | 1.13B | |
| +0.32% | -0.02% | +26.67% | +27.42% | 13.27B | |
| +0.76% | -1.22% | -23.71% | -18.40% | 7.2B | |
| -3.17% | -1.89% | -5.95% | -16.10% | 6.32B | |
| -0.91% | +0.18% | +9.61% | +29.04% | 5.69B | |
| -0.10% | +6.15% | -3.45% | +43.00% | 4.92B | |
| +2.19% | +1.60% | +2.21% | +15.63% | 4.49B | |
| -1.81% | -1.97% | +11.37% | -56.29% | 1.71B | |
| 0.00% | -5.25% | +6.98% | +15.00% | 1.47B | |
| -0.04% | +2.17% | -10.28% | -16.57% | 1.2B | |
| Average | -0.18% | -1.10% | -0.26% | -1.37% | 4.74B | |
| Weighted average by Cap. | -0.07% | -1.16% | +4.06% | +9.30% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Equities
- 688575 Stock
- Company Shenzhen YHLO Biotech Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition